Associate Professor of Breast Medical Oncology University of Texas MD Anderson Cancer Center
Oncology
Dr. Stacy L. Moulder, MD
|
|
Give Review
Stacy L. Moulder works in the field of Oncology. She studied medicine at University of Mississippi School of Medicine. Stacy Moulder is a published doctor and has 63 publications published. The lastest was: 'A sensitive lacZ-based expression vector for analyzing transcriptional control elements in eukaryotic cells.' She accepts Medicare payments and is listed with Medicare.gov.
Publications
- Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple negative breast Cancer.
- Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors.
- Metaplastic breast Cancer: clinical overview and molecular aberrations for potential targeted therapy.
- The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer.
- Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit.
- A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced Cancer.
- Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents.
- Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer.
- Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid Tumors.
- Leptomeningeal disease and breast Cancer: the importance of tumor subtype.
- First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid Tumors.
- Anastrozole and everolimus in advanced gynecologic and Breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
- Unique molecular signatures as a hallmark of patients with metastatic breast Cancer: Implications for current treatment paradigms.
- A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications f...
- Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast Cancer.
- Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced Cancers.
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors.
- Ethnic disparities in adherence to breast Cancer survivorship surveillance care.
- Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial.
- Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced Malignancies.
- Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors.
- Posterior reversible encephalopathy syndrome: more than meets the eye.
- Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic Breast ...
- Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast Cancer.
- A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid Tumors.
- Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience.
- Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced...
- A Phase I Trial of Liposomal Doxorubicin, Bevacizumab and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies.
- Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin-Bound Paclitaxel in Cancer Patients with Predominant Hepatic Metastases: Toxicity, Pharmacokinetics,...
- PIK3CA mutations in patients with advanced Cancers treated with PI3K/AKT/mTOR axis inhibitors.
- Does the PI3K Pathway Play a Role in Basal Breast Cancer?
- Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
- A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast Cancer.
- Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast Cancer.
- A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast Cancer.
- Adjuvant biologic therapy for breast Cancer.
- A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant Tumors.
- A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).
- HER (erbB) tyrosine kinase inhibitors in the treatment of breast Cancer.
- Phase 2 study of gemcitabine and irinotecan in metastatic breast Cancer with correlatives to determine topoisomerase I localization as a predictor of response.
- Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced Malignancies: a phase I clinical trial.
- Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the Breast: biologic rationale and implications for stem-cell research in...
- Intrinsic resistance to chemotherapy in breast Cancer.
- Clinical outcomes of patients with breast Cancer in a phase I clinic: the M. D. Anderson Cancer center experience.
- Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast Cancer cells and tumors.
- Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced Cancer and dominant li...
- Development of candidate genomic markers to select breast Cancer patients for dasatinib therapy.
- Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for Breast cance...
- Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast Cancer.
- A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate Cancer.
- Ixabepilone for the treatment of taxane-refractory breast Cancer.
- Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced Malignancies.
- A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast Cancer: an Eastern Cooperative Oncology Group ...
- Targeted inhibition of farnesyltransferase in locally advanced breast Cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
- First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing Tumors.
- Improving the institutional submission and approval process for clinical research protocols in oncology.
- Advances in the treatment of breast Cancer.
- A sensitive lacZ-based expression vector for Analyzing transcriptional control elements in eukaryotic cells.
- Systemic chemotherapy for urothelial transitional cell Carcinoma: an overview of toxicity.
- Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast Cancer cells in vitro and in vivo.
- Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast Cancer.
- Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast Cancer.
Schools
Univ Of Ms Sch Of Med
University Of Ms School Of Med
Vanderbilt University Med Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Vanderbilt University -
University of Mississippi Medical Center -
University of Mississippi School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1184725111 | |
| NPPES Provider LastName | MOULDER | |
| NPPES Provider FirstName | STACY | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 253.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 8.7 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184725111 |
| Last Name Of The Provider | MOULDER |
| First Name Of The Provider | STACY |
| View All |
Similar Doctors
|
Dr. Nadya Hasham-Jiwa, DO
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sapna Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jorge R. Quesada, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joan M. Bull, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sindhu Nair, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert F. Todd, MD |
|
|
Dr. Jianjun Zhang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert Z. Orlowski, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jennifer K. Litton, MD
This Doctor is OpenDoctor Recommended.
|